Efsubaglutide alfa治疗2型糖尿病:SUPER1随机双盲安慰剂对照IIb/III期试验
SUPER1研究采用两阶段无缝适应性设计,在初诊2型糖尿病患者中评估新型长效GLP-1RA efsubaglutide alfa的疗效与安全性。IIb期选出1mg和3mg为推荐III期剂量后,III期297例患者随机接受1mg、3mg或安慰剂治疗,24周HbA1c较基线分别降低1.73%和2.15%,体重分别降低0.97%和3.14%,安全性良好。
要点
- 1mg和3mg剂量24周HbA1c降幅分别为1.73%和2.15%
- 3mg剂量24周体重较基线降低3.14%,安慰剂校正后为2.18%
- 最常见不良事件为胃肠道症状,多为轻中度
核心结论
- Efsubaglutide alfa显著改善初诊2型糖尿病患者的血糖控制并促进体重下降,安全性良好。
研究设计与样本
- 两阶段IIb/III期无缝适应性设计,IIb期140例按2:2:2:1随机接受1、2、3mg或安慰剂12周,III期297例按2:2:1随机接受1mg、3mg或安慰剂。
主要发现
- 24周HbA1c较基线降低:1mg组1.73%(95%CI -20.98, -16.83 mmol/mol),3mg组2.15%(95%CI -25.68, -21.31 mmol/mol)。
- 24周HbA1c达标率:1mg组56%(95%CI 47,65;p<0.001),3mg组68%(95%CI 59,76;p<0.001)。
- 24周空腹血糖较基线降低:1mg组2.04 mmol/l(95%CI -2.40,-1.68),3mg组2.49 mmol/l(95%CI -2.87,-2.11)。
- 24周餐后2小时血糖较基线降低:1mg组3.7 mmol/l(95%CI -4.42,-3.03),3mg组4.6 mmol/l(95%CI -5.36,-3.86)。
- 24周体重较基线降低:1mg组0.97%(95%CI -1.76,-0.18),3mg组3.14%(95%CI -3.98,-2.31)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become an important option in clinical use for type 2 diabetes due to their dual benefits of glycaemic management and metabolic improvements. Efsubaglutide alfa, a novel long-acting GLP-1RA, was developed for sustained glycaemic management. This study aimed to confirm its recommended clinical dose and evaluate its efficacy and safety in drug-naive individuals with type 2 diabetes that was inadequately managed through lifestyle interventions. METHODS: This two-stage Phase IIb/III trial employed an operationally seamless adaptive design and enrolled adults who had been newly diagnosed with type 2 diabetes and whose diabetes was inadequately managed by diet and exercise. In the Phase IIb stage, participants were randomised in a 2:2:2:1 ratio to receive once-weekly subcutaneous injections of efsubaglutide alfa (1, 2 or 3 mg) or placebo for 12 weeks. Based on an interim analysis, two recommended Phase III doses (RP3Ds) were selected by an independent data monitoring committee. In the Phase III stage, participants were randomised in a 2:2:1 ratio to receive efsubaglutide alfa at one of the two RP3Ds or to receive placebo. Participants, investigators and sponsors were masked to drug/placebo allocation throughout the trial. The primary endpoint was the change in HbA1c from baseline to week 24. Secondary endpoints included changes in body weight and metabolic parameters at weeks 24 and 52. Safety was monitored throughout. RESULTS: In the Phase IIb stage, 140 participants were randomised to efsubaglutide alfa (1 mg, n=41; 2 mg, n=39; 3 mg, n=41) or placebo (n=19). Based on interim analysis, 1 and 3 mg were selected as the RP3Ds. In the Phase III stage, 297 participants were randomised to efsubaglutide alfa (1 mg, n=118; 3 mg, n=117) or placebo (n=62). At week 24, the HbA1c reductions from baseline were -18.91 mmol/mol (1.73%) (95% CI -20.98, -16.83) with the 1 mg dose, and -23.50 mmol/mol (2.15%) (95% CI -25.68, -21.31) with 3 mg. The estimated treatment difference vs placebo was -13.71 mmol/mol (-1.26%) (95% CI -17.39, -10.06) for the 1 mg dose and -18.36 mmol/mol (-1.68%) (95% CI -22.08, -14.64) for 3 mg. Additionally, 56% of participants receiving the 1 mg dose (95% CI 47, 65; p<0.001) and 68% of participants receiving the 3 mg dose (95% CI 59, 76; p<0.001) achieved an HbA1c <53.0 mmol/mol (7.0%). There were significant reductions of fasting plasma glucose from baseline: 2.04 mmol/l (95% CI -2.40, -1.68) for the 1 mg dose, and 2.49 mmol/l (95% CI -2.87, -2.11) for 3 mg (estimated treatment difference vs placebo: -1.71 mmol/l [95% CI-2.34, -1.07] for the 1 mg dose, and -2.16 mmol/l [95% CI -2.80, -1.52] for 3 mg). There were also significant reductions in 2 h postprandial plasma glucose compared with the baseline: 3.7 mmol/l (95% CI -4.42, -3.03] for the 1 mg dose, and 4.6 mmol/l (95% CI -5.36, -3.86) for 3 mg (estimated treatment difference vs placebo: -3.2 mmol/l [95% CI -4.41, -1.98] for the 1 mg dose, and -4.1 mmol/l [95% CI -5.28, -2.88] for 3 mg). Body weight decreased by 0.97% (95% CI -1.76, -0.18) with the 1 mg dose and by 3.14% (95% CI -3.98, -2.31) with 3 mg (estimated treatment difference vs placebo: 0.97% [95% CI -0.41, 2.35] for the 1 mg dose, and -2.18% [95% CI -3.30, -1.05] for 3 mg). Gastrointestinal symptoms, including nausea, vomiting, diarrhoea and decreased appetite, were the most common adverse events, and were mostly mild to moderate in severity. CONCLUSIONS/INTERPRETATION: Efsubaglutide alfa significantly improved glycaemic management and promoted weight loss in drug-naive individuals with type 2 diabetes, with a favourable safety profile. These results establish efsubaglutide alfa as a promising therapeutic option for type 2 diabetes and related metabolic disorders. TRIAL REGISTRATION: ClinicalTrials.gov NCT04994288 FUNDING: This study was sponsored by Innogen Pharmaceutical Co. Ltd.
引用
- Zhu D, Ma J, Wang W, et al. Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial. Diabetologia. 2025. PMID: 41272211. doi:10.1007/s00125-025-06593-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。